SynthesisThe Indian journal of medical research2025
Efficacy & safety of stem cell therapy for treatment of acute myocardial infarction: A systematic review & meta-analysis.
Synthesis in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objectives Stem cell based therapeutic treatments have been used as a management strategy for acute myocardial infarction (AMI), a common primary factor causing death globally. We aimed to undertake a meta-analysis of studies including randomised controlled trials (RCTs) examining different stem cell preparations in AMI, as a definitive answer from this therapeutic approach is yet to emerge. Methods Following PROSPERO registration (CRD42024628552), a systematic search was conducted through PubMed database, Embase, Cochrane, and Web of Science. Data was analysed using RevMan 5.4.1. Primary outcomes included all-cause mortality, recurrent myocardial infarction (Re-MI), severe adverse events (SAEs), hospitalisation for heart failure, cancer incidence, and left ventricular ejection fraction (LVEF). A fixed-effect model was used to assess six outcomes: all-cause mortality, Re-MI, SAEs, heart failure hospitalisation, cancer incidence, and stroke. A model based on random effects depending on heterogeneity was used to assess LVEF. Results From 9,516 records, 48 studies were included for analysis based on available endpoints. No notable changes in all-cause mortality were observed between patients receiving stem cell therapy and those in the control group, according to the meta-analysis. [Risk Ratio (RR) 0.73], SAEs (RR 0.93), Re-MI (RR 0.67), HF-related hospitalisation (RR 0.79), cancer (RR 0.82), or stroke (RR 0.81). Echocardiographic LVEF improved significantly at study end [Mean difference (MD) 2.53%] and difference from baseline (MD 3.89%), with high heterogeneity (I2 - 76%). MRI-assessed LVEF showed no significant change at study end (MD 0.83%) but improved from baseline (MD 1.37%). Heterogeneity was low except for LVEF, with serious bias risk for most outcomes and very serious for Re-MI and SAEs, though their objective nature limits bias Interpretation & conclusions Analysis done found no significant benefit of stem cell-based therapies on clinical endpoints in AMI patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.